| Followers | 200 |
| Posts | 25597 |
| Boards Moderated | 0 |
| Alias Born | 04/03/2010 |
Wednesday, May 26, 2021 2:53:15 PM
The PR basically from a few days previous was also clearly intended to stop rumors. That she addressed a rumor that was loudly being suggested not just for ASCO, but for the ASM seems to be consistent with the care they are taking to be clear that no one knows. It does not suggest a Reg FD violation that involved an insider. That’s another rumor.
First it was ASM, she released a PR addressing that there was a clear process, which squashed the ASM rumor, so the next event became the natural object of rumors, and at the ASM she squashed it.
If there had been a presentation scheduled or placeholder paper filed, they could easily explain again that those were merely placeholders put in place in anticipation. But the reality is, they can’t really SAY anything, so we see it and speculate on these things and the when they do not happen, we know it was a placeholder.
But, as for this new theory of a regulatory violation, I see no basis in your explanation or anyone else’s explanation. Seems like just another rumor.
First it was ASM, she released a PR addressing that there was a clear process, which squashed the ASM rumor, so the next event became the natural object of rumors, and at the ASM she squashed it.
If there had been a presentation scheduled or placeholder paper filed, they could easily explain again that those were merely placeholders put in place in anticipation. But the reality is, they can’t really SAY anything, so we see it and speculate on these things and the when they do not happen, we know it was a placeholder.
But, as for this new theory of a regulatory violation, I see no basis in your explanation or anyone else’s explanation. Seems like just another rumor.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
